Lilly to Invest $1B in India to Expand Manufacturing Capacity

Eli Lilly and Co. plans to invest more than $1 billion in India to expand manufacturing and supply through local drugmakers, as reported by Reuters. 

Lilly aims to increase availability of key drugs for obesity, diabetes, Alzheimer’s, cancer and autoimmune conditions, according to the company. The company launched its weight-loss drug Mounjaro in India this year and does not currently operate its own manufacturing facility in the country.

“We are making significant investments to increase manufacturing and medicine supply capacity around the world,” Patrik Jonsson, president of Lilly International, said, adding, India is a hub for capability building within its global network.

“Lilly is actively engaging with contract manufacturers in India,” the company told Reuters.

Lilly recently announced a $5 billion investment in a new facility in Virginia, part of a $27 billion expansion plan to build four new U.S. plants over the next five years.